Ambuja Cements (AMBUJACEM) — Financial Results

Ambuja Cements reported Q4 FY25 revenue of ₹9,889 crores, up 11% YoY, with EBITDA at ₹1,868 crores and 19% margin. Consolidated cash stood at ₹10,125 crores, supporting expansion to 118 million tons capacity by FY26 and 140 million tons by FY28. The company achieved 100 million tons cement capacity and secured 367 million tons new limestone reserves. Operational costs are being reduced by INR500 per ton, with INR150-175 already realized. Renewable energy capacity reached 99 megawatts, targeting 1 gigawatt by FY28. Industry demand is projected to grow 8% in FY26.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AMBUJACEM ✨ Ask AI About This

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

💡 Ask AI about this filing

"How does this financial results affect Ambuja Cements Limited's outlook?" "What did Ambuja Cements Limited announce on 6 May 2025?" "Is this positive or negative for AMBUJACEM?"

Ask AI Free →

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

🔥 Also filed on 6 May 2025

BRITANNIA Britannia Industries Limited Financial Results CHOLAFIN Cholamandalam Investment and Finance Company Limited Financial Results SBIN State Bank of India Financial Results UNIONBANK Union Bank of India Financial Results BANKBARODA Bank of Baroda Corporate Action GODREJCP Godrej Consumer Products Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.